Intranasal Ketamine in Ultra-REsistant Depression (SURE-ECT Non Responders)
Status:
Recruiting
Trial end date:
2024-04-25
Target enrollment:
Participant gender:
Summary
Despite the known efficacy of pharmacotherapy (i.e. antidepressants) and psychotherapeutic
interventions in treating depressive disorders, research evidence suggests that 20% to 40% of
patients with major depressive disorder (MDD) do not respond adequately to such treatments.
These patients are diagnosed with Treatment-Resistant Depression (TRD), and are sometimes
treated with Electroconvulsive therapy (ECT). However, about 10-30% of TRD patients do not
respond to ECT, and are thus diagnosed with Ultra-Resistant Depression (URD). Using an open
label pilot study involving subjects with URD, this trial aims to assess the safety,
tolerability, and clinical effects of intranasal ketamine (IN) treatment for this population.
Intranasal ketamine (IN) treatment approach has shown promising therapeutic outcomes for
patients with TRD, but has not yet been studied on patients with URD.